Product Information
ALOGLIPTIN 12.5 MG TABLET is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $4.9568 per EA under NDC 45802010365. Its NADAC has been published 498 times since Mar 22, 2017.
FDA first approved this application on Jan 25, 2013.
Strength
12.5 mg/1
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802010365
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ALOGLIPTIN BENZOATEApproval Type
Authorized Generic (NDA)
FDA Application
NDA022271FDA Approved
1/25/2013
On Market Since
4/8/2016
Pharmacological Classes
Price Statistics
The NADAC for ALOGLIPTIN 12.5 MG TABLET has been published 498 times since Mar 22, 2017, and over the history we have for it it has declined 14.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.9568 per EA |
|---|---|
| All-time high | $6.1823 (Feb 14, 2018) |
| All-time low | $4.2188 (Jul 17, 2024) |
| 52-week high | $5.0543 |
| 52-week low | $4.5420 |
| Median price | $5.2540 |
| Average price | $5.2915 |
| Largest weekly change | -15.0% (Mar 20, 2019) |
| Weeks tracked | 498 |
| Tracking since | Mar 22, 2017 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Alogliptin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Alogliptin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Dipeptidyl Peptidase 4 Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ALOGLIPTIN 12.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ALOGLIPTIN 12.5 MG TABLET, manufactured by Padagis Israel Pharmaceuticals Ltd, is $4.9568 per EA (NDC 45802010365), effective Sep 30, 2026.
How has the price of ALOGLIPTIN 12.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for ALOGLIPTIN 12.5 MG TABLET has declined 14.6%. It has been tracked across 498 weekly CMS publications since Mar 22, 2017.
What are the highest and lowest recorded NADAC prices for ALOGLIPTIN 12.5 MG TABLET?
Since Mar 22, 2017, the NADAC for ALOGLIPTIN 12.5 MG TABLET has ranged from a low of $4.2188 (Jul 17, 2024) to a high of $6.1823 (Feb 14, 2018), with a median of $5.2540 per EA.
Are there cheaper alternatives to ALOGLIPTIN 12.5 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of ALOGLIPTIN 12.5 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ALOGLIPTIN 12.5 MG TABLET?
ALOGLIPTIN 12.5 MG TABLET (NDC 45802010365) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.